期刊文献+

口服降糖药临床应用分析 被引量:8

Utilization of Oral Hypoglycemic Drugs
下载PDF
导出
摘要 目的:分析常熟医院口服降糖药应用现状和趋势。方法:对2007—2009年我院口服降糖药应用品种、销售金额、用药频度(DDDs)和日均费用(DDC)进行回顾性分析。结果:3年口服降糖药销售金额占抗糖尿病药总金额48.12%;销售金额排序前3位的依次是:磺酰脲类、非磺酰脲类胰岛素促泌剂和α-糖苷酶抑制剂;DDDs排序前3位的依次是:磺酰脲类、双胍类和非磺酰脲类胰岛素促泌剂;3年中,阿卡波糖、瑞格列奈和格列吡嗪缓释片位列单品种销售金额前3位;格列吡嗪缓释片、二甲双胍和格列吡嗪普通片位列单品种DDDs的前3位;噻唑烷二酮类的DDC最高,双胍类最低。结论:我院口服降糖药用药合理且占主导地位。 OBJECTIVE:To evaluate the status quo and tendency of utilization of oral hypoglycemic drugs in our hospital.METHODS:The use of oral hypoglycemic drugs used in our hospital during 2007-2009 was analyzed retrospectively in terms of drug varieties,consumption sum,DDDs and DDC etc.RESULTS:The consumption sum of oral hypoglycemic drugs represented 48.12% of that for all hypoglycemic drugs,leading the first 3 places were sulfonylurea,non-sulfonylurea insulin secretagogue drugs and α-glucosidase inhibitors.Leading the first 3 places on the list of DDDs were sulfonylurea,biguanides and non-sulfonylurea insulin secretagogue drugs.Over the 3 years,leading the top 3 on the consumption list of all the single kind of hypoglycemic drugs were acarbose,repaglinide and glipizide sustained release tablets,and leading the top 3 on the DDDs list for all the single hypoglycemic drugs were glipizide sustained release tablets,metformin and glipizide compressed tablets.The DDC of thiazolidinediones was the higtest and that of metformin was the lowest.CONCLUSION:The use of oral hypoglycemic drugs was rational and predominant in our hospital.
出处 《中国医院用药评价与分析》 2010年第11期990-992,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 口服降糖药 销售金额 用药频度 日均费用 药物利用 Oral hypoglycemic drugs; Consumption sum; DDDs; DDC; Drug utilization
  • 相关文献

参考文献9

二级参考文献37

  • 1吴胜亮,马广玲,丁云川.2型糖尿病胰岛素治疗措施应用及评价[J].中国新医药,2004,3(9):27-28. 被引量:1
  • 2吴佩芬.口服降糖药物应用趋势分析[J].首都医药,2004,11(14):44-46. 被引量:2
  • 3曲彩红,杨莉,陶玲,朱惠敏,张永明,师晓嘉.2000年~2003年广东地区44家医院降糖药利用分析[J].中国药房,2005,16(1):42-44. 被引量:34
  • 4张继春,金岩,李大魁,彭名炜.北京地区主要抗生素使用频度分析[J].中国药学杂志,1994,29(6):373-376. 被引量:34
  • 5刘屏,张志萍,陈宜鸿,孙映和,颜青,李辉.我院门诊处方中抗菌药物使用研究[J].中国药房,1995,6(2):23-24. 被引量:15
  • 6[1]Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the βcell sulfonylurea receptor Ⅱ.Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochim Biophys Acta, 1994, 1191(2):278
  • 7[2]Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor Ⅰ. Binding characteristics. Biochim Biophys Acta, 1994,1191(2):267
  • 8[3]Massi-Bendetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type Ⅱ diabetic patients treated with glimepiride and glibenclamide. Horm Metab Res, 1996,28(9) :451
  • 9[4]Geisen K, Vegh A, Krause E, et al. Cardiovascular effects of conventional sulfony1ureas and glimepiride. Horm Metab Res,1996, 28(9):496
  • 10[5]Bijlstra PJ, Lutterman JA, Rusel FG, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia, 1996, 39 (9):1083

共引文献1557

同被引文献44

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部